| 中文名称: | 夫罗曲坦琥珀酸盐 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | Frovatriptan succinate | ||||
| 别名: | 夫罗曲普坦琥珀酸盐;琥珀酸福伐曲坦 1G;琥珀酸福伐曲坦(琥珀酸夫罗曲坦);琥珀酸夫罗曲坦;夫罗曲坦-D3琥珀酸;二氧磷基腈氟化三聚体;琥珀酸福伐曲坦 (R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate | ||||
| CAS No: | 158930-09-7 | 分子式: | C18H23N3O5 | 分子量: | 361.39 |
| CAS No: | 158930-09-7 | ||||
| 分子式: | C18H23N3O5 | ||||
| 分子量: | 361.39 | ||||
基本信息
|
产品编号： |
F10332 |
||||
|
产品名称： |
Frovatriptan succinate |
||||
|
CAS: |
158930-09-7 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
361.39 |
|
|
||
|
化学名： |
butanedioic acid;(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
72 mg/mL (199.23mM) |
|||
|
Water |
72 mg/mL (199.23mM) |
||||
|
Ethanol |
Insoluble |
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
2.7671mL |
13.8355mL |
27.6709mL |
|
5mM |
0.5534mL |
2.7671mL |
5.5342mL |
|
10mM |
0.2767mL |
1.3835mL |
2.7671mL |
|
50mM |
0.0553mL |
0.2767mL |
0.5534mL |
生物活性
|
产品描述 |
一种强效，高亲和力，选择性和具有口服活性的 5-HT1B (pK50 为 8.2) 和 5-HT1D 受体激动剂，选择性是 5-HT1A，5-HT1F 和 5-HT7 的 10 倍以上，是其他 5-HT，多巴胺，组胺 H1 和 α1-肾上腺素受体的 1000 倍以上。Frovatriptan succinate 可用于偏头痛的研究。 |
|
|
靶点 |
5-HT1B Receptor 8.2 (pEC50) |
5-HT1D Receptor |
|
体外研究 |
Cerebral vasodilatation and neurogenic inflammation are considered to be prime movers in the pathogenesis of migraine. Activation of 5-HT1B reverses cerebral vasodilatation and activation of 5-HT1D prevents neurogenic inflammation. Frovatriptan has a high affinity for 5-HT1B and 5-HT1D receptors and a moderate affinity for the 5-HT1A and 5-HT1F receptors subtypes. Frovatriptan has a moderate affinity for the 5-HT7 receptors, an action associated with coronary artery relaxation in the dog. |
|
|
体内研究 |
Oral bioavailability of Frovatriptan is 22%-30% and is not affected by food. Although the maximum concentration in the plasma is achieved in 2-3 hours, 60%-70% of this is achieved in 1 hour. A steady state is achieved in 4-5 days. Plasma protein binding is low at 15%. The most unique feature is the relative terminal long half-life of about 26 hours. Frovatriptan is chiefly metabolized by CYP1A2 and is cleared by the kidney and liver making moderate failure of either organ not a limiting factor in treatment. Frovatriptan (0.1, 0.2, and 0.3 mg/kg; a single bolus intraduodenal administration) treatment produces an increase in carotid vascular resistance, which is sustained for at least 5 hours in dogs. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
